
AbbVie (ABBV) Stock Forecast & Price Target
AbbVie (ABBV) Analyst Ratings
Bulls say
AbbVie is supported by durable growth in immunology, where Skyrizi and Rinvoq continue to post strong prescription gains and help offset the legacy Humira decline, while the company’s 2026 guidance and EPS outlook reflect solid operating momentum. It also benefits from a broadening portfolio in neuroscience and oncology, with Vyalev showing rapid TRx growth and added scale from the 2020 Allergan deal plus the 2024 Cerevel and ImmunoGen acquisitions, which reduce concentration risk and deepen the pipeline. With strong cash generation, a roughly 3% dividend, and valuation that appears attractive relative to its growth profile, the company presents a compelling fundamental case.
Bears say
AbbVie is exposed to a tougher fundamental setup as government pricing pressure and IRA headwinds are eroding oncology net pricing, while Imbruvica is expected to decline 20% in net pricing and 14% in TRx, more than offsetting Venclexta’s 8% sales growth despite 30% TRx growth. The company’s immunology base is still concentrated in Skyrizi and Rinvoq, but increasing competition, low single-digit price headwinds, and patent risk threaten durability just as 2Q26 revenue is expected at $16.65bn versus $16.76bn consensus and EPS is near the low end of guidance. Added acquisition and integration costs, including $3.7bn in upfront charges in nine months of 2025, plus product-liability and antitrust overhangs, reinforce the view that margins and valuation face sustained pressure.
This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares